Skip to main content
Top
Published in: Endocrine 3/2020

01-09-2020 | Magnetic Resonance Imaging | Clinical Management of Endocrine Diseases

Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation

Authors: Athanasios D. Anastasilakis, Gerasimos Evangelatos, Polyzois Makras, Alexios Iliopoulos

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Introduction

Patients discontinuing or neglecting denosumab treatment are at risk of sustaining rebound-associated vertebral fractures (RAVFs). In everyday clinical practice, conventional X-rays are used to diagnose such events in patients reporting acute back pain.

Patients

Herein we report the cases of two patients, in whom magnetic resonance imaging (MRI) depicted more RAVFs or allowed earlier detection of RAVFs compared with conventional X-rays.

Conclusion

It seems that, in the setting of RAVFs following denosumab discontinuation, MRI imaging provides better accuracy in the diagnostic process and in the classification assessment compared to conventional X-rays, thus allowing an earlier and clearer picture of the magnitude of spinal damage. This could have an impact on clinical decisions and improve patient’s management.
Literature
1.
go back to reference H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8, 1137–48 (1993)CrossRef H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8, 1137–48 (1993)CrossRef
2.
go back to reference F. Grados, C. Roux, M.C. de Vernejoul, G. Utard, J.L. Sebert, P. Fardellone, Comparison of four morphometric definitions and a semiquantitative consensus reading for assessing prevalent vertebral fractures. Osteoporos. Int. 12, 716–22 (2001)CrossRef F. Grados, C. Roux, M.C. de Vernejoul, G. Utard, J.L. Sebert, P. Fardellone, Comparison of four morphometric definitions and a semiquantitative consensus reading for assessing prevalent vertebral fractures. Osteoporos. Int. 12, 716–22 (2001)CrossRef
3.
go back to reference G. Marongiu, S. Congia, M. Verona, M. Lombardo, D. Podda, A. Capone, The impact of magnetic resonance imaging in the diagnostic and classification process of osteoporotic vertebral fractures. Injury 49(Suppl 3), S26–S31 (2018)CrossRef G. Marongiu, S. Congia, M. Verona, M. Lombardo, D. Podda, A. Capone, The impact of magnetic resonance imaging in the diagnostic and classification process of osteoporotic vertebral fractures. Injury 49(Suppl 3), S26–S31 (2018)CrossRef
4.
go back to reference U.J. Spiegl, R. Beisse, S. Hauck, A. Grillhosl, V. Buhren, Value of MRI imaging prior to a kyphoplasty for osteoporotic insufficiency fractures. Eur. Spine J. 18, 1287–92 (2009)CrossRef U.J. Spiegl, R. Beisse, S. Hauck, A. Grillhosl, V. Buhren, Value of MRI imaging prior to a kyphoplasty for osteoporotic insufficiency fractures. Eur. Spine J. 18, 1287–92 (2009)CrossRef
5.
go back to reference A.D. Anastasilakis, S.A. Polyzos, P. Makras, Therapy of endocrine disease: denosumab vs. bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31–R45 (2018)CrossRef A.D. Anastasilakis, S.A. Polyzos, P. Makras, Therapy of endocrine disease: denosumab vs. bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31–R45 (2018)CrossRef
6.
go back to reference H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwinski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017)CrossRef H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwinski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017)CrossRef
7.
go back to reference A.D. Anastasilakis, M.P. Yavropoulou, P. Makras, G.T. Sakellariou, F. Papadopoulou, S. Gerou, S.E. Papapoulos, Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur. J. Endocrinol. 176, 677–683 (2017)CrossRef A.D. Anastasilakis, M.P. Yavropoulou, P. Makras, G.T. Sakellariou, F. Papadopoulou, S. Gerou, S.E. Papapoulos, Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur. J. Endocrinol. 176, 677–683 (2017)CrossRef
8.
go back to reference A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Miner. Res. 32, 1291–1296 (2017)CrossRef A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Miner. Res. 32, 1291–1296 (2017)CrossRef
9.
go back to reference S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.B. Jensen, M. McClung, C. Roux, O. Torring, I. Valter, A.T. Wang, J.P. Brown, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190–198 (2018)CrossRef S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.B. Jensen, M. McClung, C. Roux, O. Torring, I. Valter, A.T. Wang, J.P. Brown, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190–198 (2018)CrossRef
10.
go back to reference A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman-Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J. Bone Miner. Res. 34, 2220–2228 (2019)CrossRef A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman-Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J. Bone Miner. Res. 34, 2220–2228 (2019)CrossRef
11.
go back to reference M.R. McClung, R.B. Wagman, P.D. Miller, A. Wang, E.M. Lewiecki, Observations following discontinuation of long-term denosumab therapy. Osteoporos. Int. 28, 1723–1732 (2017)CrossRef M.R. McClung, R.B. Wagman, P.D. Miller, A. Wang, E.M. Lewiecki, Observations following discontinuation of long-term denosumab therapy. Osteoporos. Int. 28, 1723–1732 (2017)CrossRef
12.
go back to reference J. Leroux, P.H. Vivier, M. Ould Slimane, E. Foulongne, S. Abu-Amara, J. Lechevallier, J. Griffet, Early diagnosis of thoracolumbar spine fractures in children. A prospective study. Orthop. Traumatol. Surg. Res. 99, 60–65 (2013)CrossRef J. Leroux, P.H. Vivier, M. Ould Slimane, E. Foulongne, S. Abu-Amara, J. Lechevallier, J. Griffet, Early diagnosis of thoracolumbar spine fractures in children. A prospective study. Orthop. Traumatol. Surg. Res. 99, 60–65 (2013)CrossRef
13.
go back to reference R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono, A. Sudo, Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos. Int. 29, 769–772 (2018)CrossRef R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono, A. Sudo, Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos. Int. 29, 769–772 (2018)CrossRef
14.
go back to reference A.W. Popp, P.K. Zysset, K. Lippuner, Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos. Int. 27, 1917–1921 (2016)CrossRef A.W. Popp, P.K. Zysset, K. Lippuner, Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos. Int. 27, 1917–1921 (2016)CrossRef
15.
go back to reference K.M. Qasem, A. Suzuki, K. Yamada, M. Hoshino, T. Tsujio, S. Takahashi, H. Nakamura, Discriminating imaging findings of acute osteoporotic vertebral fracture: a prospective multicenter cohort study. J. Orthop. Sur. Res 9, 96 (2014)CrossRef K.M. Qasem, A. Suzuki, K. Yamada, M. Hoshino, T. Tsujio, S. Takahashi, H. Nakamura, Discriminating imaging findings of acute osteoporotic vertebral fracture: a prospective multicenter cohort study. J. Orthop. Sur. Res 9, 96 (2014)CrossRef
Metadata
Title
Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation
Authors
Athanasios D. Anastasilakis
Gerasimos Evangelatos
Polyzois Makras
Alexios Iliopoulos
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02333-1

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.